Product Highlight - Tagrisso

Active ingredient: Osimertinib mesylate.

Indication: 1st-line treatment of patients w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) w/ activating epidermal growth factor receptor (EGFR) mutations. Locally advanced or metastatic EGFR T790M mutation-positive NSCLC. Adjuvant therapy after tumour resection in patients w/ NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.

Dosage & Administration: 80 mg once daily, may be reduced to 40 mg once daily if necessary.